Regulonix is an early-stage biotechnology company developing non-opioid drugs for chronic pain. By indirectly targeting the sodium channel NaV1.7 – a well-established and genetically validated pain target – and focusing on the signaling pathways that control this channel’s activity, the Regulonix team has isolated compounds demonstrated in animal models to be non-addictive and more effective than morphine. 

Biotechnology

Regulonix Holding

Regulonix Holding's headquarters in Tucson, AZ, United States

Regulonix Holding's Leadership Team includes Rajesh Khanna.

Leadership Team

This department provides expert guidance and strategic counsel to support organizational decision-making.

��

People (1)

Jobs (0)

Other teams

Advisory Services

��������

People (1)

Jobs (0)

Other teams

Advisory Services

��